Coherus BioSciences

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Coherus BioSciences targets profitability in 2024 with strong product focus

Coherus BioSciences is strategically positioned to achieve profitability in 2024 through revenue growth and cost control. The company's strong product portfolio and focus on user-friendly solutions provide a competitive edge. Challenges include competition and regulatory approvals, while opportunities exist in expanding product approvals and optimizing expenses.

Coherus BioSciences reports robust Q1 results and eyes market expansion

Coherus BioSciences showcased strong financial performance, product advancements, and strategic initiatives during their Q1 2023 Earnings Call, positioning them for future growth.
While facing challenges such as potential competition and pricing uncertainties, the company's strengths in product diversity, patient engagement, and commercial readiness offer a solid foundation for success.
By capitalizing on opportunities like FDA approvals, therapy combinations, and market share goals, Coherus can navigate challenges and drive innovation in the biopharmaceutical market.

Coherus BioSciences posts robust Q2 earnings, eyes market expansion

Coherus BioSciences reported strong Q2 2023 performance with net product revenues of $58.5 million.
The company aims to achieve cash flow positivity in 2024 through expense management and revenue growth.
Focus on offering low-cost alternatives like CIMERLI and expanding market share for key products.
Plans to leverage the successful launches of UDENYCA and Toripalimab for future growth opportunities.

Coherus BioSciences reports strong Q3 revenue growth and profitability focus

Coherus BioSciences showed strong revenue growth and expense management focus for profitability.
Key products like CIMERLI and UDENYCA drove revenue growth in Q3 2023.
Adjusting R&D expenses to align with revenue and focusing on profitability until mid-2024.
Analysts raised questions on pricing dynamics, profitability goals, and pipeline development plans.

Coherus BioSciences reports strong Q4 results and focuses on growth

Coherus BioSciences showcased strong Q4 results, focusing on efficiency and growth in 2024.
The company achieved FDA approvals for key products, with UDENYCA sales showing growth and LOQTORZI gaining traction.
Financials highlighted cost reductions and pipeline progress, with a cautious approach to revenue projections.
Emphasis on controlling expenses, reducing debt, and driving revenues higher while investing in key products.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

– YUSIMRY™ (adalimumab-aqvh), Coherus' second product, approved by FDA on December 17, 2021 – – BLAs under FDA review for PD-1 inhibitor toripalimab and CIMERLI™ (ranibizumab-ranq) – – New FDA filings expected in 2022 for UDENYCA® on-body injector and additional toripalimab indications – – UDENYCA® delivered net sales of $73 million in 4Q 2021; $327 million in FY 2021 – – Conference call and webcast today at 5:00 p.m. ET –

Coherus BioSciences Reports Fourth Quarter and Full Year 2021 Results

REDWOOD CITY, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) today announced Paul Reider has been named Chief Commercial Officer. Mr. Reider previously held the position of Executive Vice President of Commercial Operations and Market Access.

Coherus Names Paul Reider Chief Commercial Officer

REDWOOD CITY, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its fourth quarter and full year 2021 financial results will be released after market close on Thursday, February 17, 2022. Starting at 5 p.m. ET, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.

Coherus BioSciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 17th, 2022

Jim Healy, Director since 2014, steps down from the Coherus board Jim Healy, Director since 2014, steps down from the Coherus board

Coherus BioSciences Appoints Health Care Payer Expert Lee N. Newcomer, M.D.

Balance sheet strengthened to support commercial launches of as many as five new products in 2022 and 2023 Balance sheet strengthened to support commercial launches of as many as five new products in 2022 and 2023

Coherus BioSciences Secures Credit Financing with Pharmakon Advisors

REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 9 a.m. EST / 6 a.m. PST.

Coherus BioSciences Management to Present at the 40th Annual J.P. Morgan Healthcare Conference

- Approved for all eligible indications of the reference biological product, Humira® (adalimumab) -

Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)

REDWOOD CITY, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Theresa LaVallee, Ph.D. as its Chief Development Officer. Dr. LaVallee will serve as a member of the Company's executive leadership team and oversee all regulatory matters and product development functions, reporting to Denny Lanfear, President and CEO of Coherus.

Coherus BioSciences Appoints Theresa LaVallee, Ph.D., Chief Development Officer

The FDA bestows an Orphan Drug designation to Coherus (CHRS) and partner Junshi's toripalimab for the treatment of esophageal cancer.

Coherus' (CHRS) Toripalimab Gets Orphan Drug Tag for Rare Cancer

Coherus BioSciences, Inc. (CHRS) CEO Dennis Lanfear on Q3 2021 Results - Earnings Call Transcript

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -22.50% and -5.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Coherus BioSciences (CHRS) Reports Q3 Loss, Misses Revenue Estimates

Coherus BioSciences (NASDAQ:CHRS) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM. Here's what investors need to know about the announcement.

Recap: Coherus BioSciences Q3 Earnings

– Key milestones achieved driving near-term commercial product portfolio expansion –

Coherus BioSciences Reports Third Quarter 2021 Results

REDWOOD CITY, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the Centers for Medicare & Medicaid Services (“CMS”) will continue to provide increased Medicare reimbursement in the 340B outpatient hospital setting through year-end 2022 for 28 drugs, biologics and devices impacted by the COVID-19 public health emergency, including UDENYCA® (pegfilgrastim-cbqv).

Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022

REDWOOD CITY, Calif., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2021 financial results will be released after market close on Monday, November 8, 2021. Starting at 5 p.m. ET, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.

Coherus BioSciences to Report Third Quarter 2021 Financial Results on November 8th

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Coherus BioSciences (CHRS) Q3 Earnings Expected to Decline

Coherus makes a lot of money from its biosim business. Its foray into R&D is slowly getting derisked with positive data.

Coherus BioSciences: Dependable Stock With A Possibility Of Appreciation

REDWOOD CITY, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- It is with profound sadness that Coherus BioSciences, Inc. (Nasdaq: CHRS) announces the unexpected passing of board member Alan C. Mendelson. He had been a director of the Company since January 2021 and had previously served as external legal counsel since its founding in 2010.

Coherus BioSciences Mourns the Passing of Board Member Alan C. Mendelson

- UDENYCA ® On-Body Injector (OBI) Achieved Both Pharmacokinetic and Pharmacodynamic Bioequivalence in Randomized Clinical Trial

Coherus Announces Positive Results of UDENYCA® On-Body Injector Clinical Trial

REDWOOD CITY, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the United States Food and Drug Administration (FDA) has accepted for review the 351(k) Biologics License Application (BLA) for CHS-201, a biosimilar candidate of reference product Lucentis® (ranibizumab). The FDA has set a Biosimilar User Fee Act action date for August 2, 2022, and, if approved, Coherus plans to launch the Lucentis biosimilar in the U.S. in the second half of 2022. The BLA for CHS-201 (also known as FYB201) was submitted by Coherus' partner, Bioeq AG, from whom Coherus acquired U.S. commercial rights in 2019.

Coherus Announces BLA Filing for Lucentis® (ranibizumab) Biosimilar Candidate Accepted by FDA for Review

REDWOOD CITY, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- It is with profound sadness that Coherus BioSciences, Inc. (Nasdaq: CHRS) announces the passing of board member Samuel Nussbaum, M.D. During his distinguished career, Dr. Nussbaum worked as a physician, researcher, professor, and healthcare executive. He had been a director of the Company since May 2018.

Coherus BioSciences Mourns the Passing of Board Member Dr. Samuel Nussbaum

REDWOOD CITY, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 23rd Annual H.C. Wainwright Global Investment Conference. The presentation will be made available at 7 a.m. ET on Tuesday, September 14, 2021, during the virtual conference.

Coherus Management to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

The stock price of Coherus BioSciences, Inc. (Nasdaq: CHRS) increased 3.71% yesterday and is up more than 1% pre-market today. This is why it happened.

CHRS Stock: Why It Increased Yesterday And Today

Coherus BioSciences (CHRS) and partner Junshi announce positive data from a late-stage study on toripalimab for the first-line treatment of NSCLC.

Coherus (CHRS), Junshi Announce Positive NSCLC Study Results

– Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone –

Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

News for Coherus BioSciences Stock (CHRS)